Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC

This is a multicenter, open-label, prospective, single-arm, phase II study designed to evaluate the efficacy and safety of neoadjuvant zanidatamab combined with tislelizumab and chemotherapy, followed by selective bladder preservation, in patients with HER2-positive muscle-invasive bladder cancer (MIBC) staged cT2-4aN0-1M0.

NCT Number	NCT07296705
Lead Sponsor	Fujian Medical University Union Hospital Collaborators: BeiGene
Conditions	Muscle Invasive Bladder Cancer (MIBC)
Enrollment	25 participants
Start Date	2025-10-25
Primary Completion	2027-12 (estimated)
Study Completion	2029-12 (estimated)
Updated on ClinicalTrials.gov	2025-12-22